Novartis ' knockoff of Biogen ' s Tysabri is first MS biosim in US

Two months after a federal court in Delaware rejected Biogen’s patent infringement c | The FDA has endorsed Novartis' Tyruco as the first U.S. biosimilar to treat multiple sclerosis. The copycat will compete with Biogen's Tysabri, covering all of the original drug's indications for relapsing MS in…#delaware #biogen #fda #novartis #tysabri #crohn
Source: Reuters: Health - Category: Consumer Health News Source Type: news